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Abstract  70 
Background & Aims: Effects of long-chain omega-3 (LCn3) and omega-6 fatty acids on prevention 71 
and treatment of inflammatory bowel diseases (IBD, including Crohn’s Disease, CD and ulcerative 72 
colitis, UC), and inflammation are unclear. We systematically reviewed long-term effects of omega-73 
3, omega-6 and total polyunsaturated fats (PUFA) on IBD diagnosis, relapse, severity, 74 
pharmacotherapy, quality of life and key inflammatory markers. 75 
Methods: We searched Medline, Embase, Cochrane CENTRAL, and trials registries, including RCTs 76 
in adults with or without IBD comparing higher with lower omega-3, omega-6 and/or total PUFA 77 
intake for ≥24 weeks that assessed IBD-specific outcomes or inflammatory biomarkers. 78 
Results: We included 83 RCTs (41,751 participants), of which 13 recruited participants with IBD.  79 
Increasing LCn3 may reduce risk of IBD relapse (RR 0.85, 95% CI 0.72 to 1.01) and IBD worsening 80 
(RR 0.85, 95% CI 0.71 to 1.03), and reduce erythrocyte sedimentation rate (ESR, SMD -0.23, 95% CI 81 
-0.44 to -0.01), but may increase IBD diagnosis risk (RR 1.10, 95% CI 0.63 to 1.92), and faecal 82 
calprotectin, a specific inflammatory marker for IBD (MD 16.1μg/g, 95% CI -37.6 to 69.8, all low-83 
quality evidence).  Outcomes for alpha-linolenic acid, omega-6 and total PUFA were sparse, but 84 
suggested little or no effect where data were available.  85 
Conclusion: This is the most comprehensive meta-analysis of RCTs investigating long-term effects 86 
of omega-3, omega-6 and total PUFA on IBD and inflammatory markers. Our findings suggest that 87 
supplementation with PUFAs has little or no effect on prevention or treatment of IBD and provides 88 
little support for modification of long-term inflammatory status.  89 
 90 
Keywords: Inflammatory bowel diseases; Dietary fats, unsaturated; Fatty acids, omega-3; Fatty 91 
acids, omega-6; Alpha-linolenic acid; meta-analysis 92 
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Introduction  94 
Crohn’s Disease (CD) and ulcerative colitis (UC), collectively ‘inflammatory bowel disease’ 95 
(IBD), are inflammatory conditions of the gastrointestinal tract. While CD and UC share relapsing-96 
remitting progression and chronic mucosal inflammation, they are distinct in clinical presentation and 97 
outcomes. Precise aetiologies of CD and UC are unclear, although environmental, gut microbiome, 98 
immune response and genetic factors predispose individuals to IBD [1]. A recent systematic review 99 
suggests that IBD prevalence is over 0.3% in North America, Oceania and many European countries, 100 
with lower but rising incidence in newly industrialised African, Asian, and South American countries 101 
[2]. IBD is expensive to individuals and healthcare systems, and has serious impacts on quality of life 102 
[3, 4]. The primary goal in clinical management of UC and CD is to induce and maintain remission 103 
[5]. Secondary goals include minimising IBD’s psychosocial impact, physical distress and depressive 104 
symptoms associated with relapse [6].  Reducing need for pharmacological maintenance (including 105 
corticosteroids, immune-suppressants and immunomodulatory medications) may be helpful as these 106 
drugs are associated with significant adverse events [7].  107 
Polyunsaturated fatty acids (PUFAs) include omega-3 and omega-6 fatty acids. Long-chain 108 
omega-3 fatty acids (LCn3) include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 109 
found in fish; while alpha-linolenic acid (ALA) is found in some plant oils (including flaxseed, some 110 
nuts and rapeseed/canola).  Many plant oils are rich in omega-6 fats, particularly linoleic acid (LA). 111 
LCn3 are thought to reduce various physiological aspects of inflammation including leucocyte 112 
chemotaxis, adhesion molecule expression, leucocyte–endothelial adhesive interactions, prostaglandin 113 
and leukotriene production from omega-6 and production of pro-inflammatory cytokines [8]. Omega-114 
6 (LA) has been correlated with pro-inflammatory effects, and its derivative arachidonic acid (AA) is 115 
a precursor for key pro-inflammatory mediators [8, 9]. Earlier case-controlled studies have reported a 116 
high levels of AA in mucosal tissues of IBD patients. While data from animal studies shown that the 117 
intake of AA have increased the severity of the inflammation in IBD [10].  Thus, LCn3 and ALA may 118 
 6 
help maintain remission, prevent or delay diagnosis of IBD, and reduce markers of inflammation, while 119 
LA and AA omega-6 fats are considered relatively pro-inflammatory.   120 
Inflammation is generally assessed in clinical practice and research by measuring biomarkers. 121 
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are used to measure systemic 122 
inflammation and are non-specific indicators for IBD [11]. CRP levels correlate better than ESR with 123 
IBD clinical activity, are measured more frequently in clinical situations and are less affected by aging 124 
[11, 12]. Faecal calprotectin is a promising site-specific biomarker, released within the intestinal 125 
mucosa during inflammation, and recommended to support differential diagnosis between IBD and 126 
non-IBD gastrointestinal inflammation [5]. Inflammatory cytokines (including interleukin-6 (IL-6) 127 
and tumour necrosis factor-α (TNF-α)) and adhesion molecules (such as intercellular adhesion 128 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)) are increased in the intestinal 129 
mucosa during inflammation and may have a role in disease pathogenesis [13, 14]. Although plasma 130 
IL-6 and CRP correlate with IBD incidence pre-clinically, and may indicate early disease status of 131 
IBD [15], they are non-specific markers of inflammation and so are potentially affected by additional 132 
variables.  133 
Additionally, increasing dietary PUFA inevitably alters the overall balance of nutrient intake 134 
and may favourably affect gut microbiota [16]. Despite strong theoretical mechanisms for utility of 135 
LCn3 and negative effects of omega-6 on IBD, the research evidence is contradictory. We aimed to 136 
systematically review effects of PUFA (LCn3, ALA, omega-6, total PUFA) on remission and relapse 137 
rates, pharmaceutical use, disease severity and incidence, and quality of life as well as key 138 
inflammatory markers in long-term trials. We were also interested in how effects varied by UC and 139 
CD, intervention type, baseline severity, dose, duration and nutrients displaced by increased PUFA.  140 
 141 
  142 
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Methods 143 
This review is part of a series by the Polyunsaturated Fats and Health (PUFAH) group 144 
commissioned by the World Health Organization (WHO) Nutrition Guidance Expert Advisory Group 145 
(NUGAG) Subgroup on Diet and Health to inform and contribute to development of WHO 146 
recommendations. We collated a large set of long-term trials of PUFAs and examined them for 147 
relevant, often unpublished, outcomes [17].  The full set of reviews assesses effects of PUFA on 148 
cardiovascular disease, cancers, inflammatory bowel disease, neurocognitive outcomes and depression 149 
[17-24]. This systematic review is registered on PROSPERO [25].  Methods for the set of PUFAH 150 
reviews were based on Cochrane and GRADE, using Review Manager 5.3 and GradePRO software 151 
[26-29], reported according to PRISMA guidelines [30]. Detailed methodology for the set of reviews, 152 
the trials database and flow diagram are described elsewhere [17], review methodology is briefly 153 
presented here.  154 
 155 
Inclusion criteria 156 
We included published and unpublished randomised controlled trials (RCTs) comparing higher 157 
with lower omega-3, omega-6 and/or total PUFA intake for ≥24 weeks and assessed our primary 158 
outcomes. Participants were adults (aged ≥18 years) with or without a diagnosis of IBD, but trials of 159 
pregnant or acutely ill participants (with current cancer, undergoing transplantation, with acquired 160 
immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV), on haemodialysis, 161 
with IgA glomerulonephritis or any renal problem) were excluded.  Eligible interventions could be 162 
dietary advice; supplementation (taken orally as oil, foods or capsules); or diet provided.  163 
Multifactorial interventions were excluded. 164 
Primary outcomes included rates of induced IBD relapse (or remission), IBD severity or 165 
worsening and inflammatory markers (CRP, ESR, IL-6 and faecal calprotectin) in studies of people 166 
with existing IBD.  In other trials primary outcomes included IBD diagnoses and inflammatory 167 
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markers. Secondary outcomes, assessed in included trials were: corticosteroid, immunosuppressant, 168 
and immuno-modulator use, measures of quality of life, other inflammatory marker levels and 169 
adiposity measures. 170 
 171 
Methods for identification of studies 172 
We searched Cochrane CENTRAL, Medline and Embase to 27th April 2017, 173 
ClinicalTrials.com and the World Health Organization International Clinical Trials Registry Platform 174 
to September 2016, and reassessed all ongoing trials in July 2019. We checked included trials of 175 
relevant systematic reviews, and wrote to authors of included studies for additional studies and trial 176 
data [17], creating a database of trials that randomised participants to increased omega-3, omega-6 or 177 
total PUFA compared to lower omega-3, omega-6 or total PUFA and assessed effects for ≥24 weeks 178 
(reflecting metabolic studies suggesting 6 months is the minimum duration of supplementation 179 
required to ensure equilibration of LCn3 into most body compartments) [31]. From this database, 180 
studies were chosen for this review that had assessed at least one primary review outcome (even when 181 
not fully reported).  182 
Study inclusion, data extraction and risk of bias were assessed independently in duplicate. We 183 
assessed Cochrane risk of bias tool domains [32] as well as risk from compliance problems and 184 
attention bias [17]. We considered dietary advice trials to be at low summary risk of bias where we 185 
judged randomisation, allocation concealment and blinding of outcome assessors adequate, and 186 
supplement trials to be at low summary risk of bias where we judged randomisation, allocation 187 
concealment, blinding of participants, personnel and outcome assessors adequate (all other trials were 188 
considered at moderate or high risk of bias).  189 
 190 
Data synthesis 191 
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Our primary analyses assessed effects of total PUFA, omega-6, LCn3 and ALA separately 192 
using random-effects meta-analysis as dietary interventions are naturally heterogeneous [33]. 193 
Treatment/control differences in outcomes were combined across studies using relative risks (RR) or 194 
mean differences (MD), measures using different units were converted to a single unit.  Data on change 195 
from baseline in each arm with standard deviations were used for continuous outcomes where 196 
available, otherwise endpoint data were used [33]. As remission is the reverse of relapse we assessed 197 
these outcomes together, using relapse as the outcome.  We ran sensitivity analyses for all primary 198 
outcomes using fixed-effect meta-analysis, limiting to studies at low summary risk of bias and at low 199 
risk of bias from compliance. Further sensitivity analysis (limiting analyses to trials randomising ≥100 200 
participants), subgrouping and funnel plots were carried out where there were at least ten trials in a 201 
meta-analysis. We noted where data were measured but not fully reported to assess potential 202 
publication bias, and partially reported data were displayed in forest plots to allow assessment of 203 
consistency with meta-analysis results. Heterogeneity was assessed using I2 and considered important 204 
where over 50% [34]. 205 
Effect sizes were interpreted as agreed with WHO NUGAG and pre-specified for this set of 206 
reviews [17]. In conjunction with Cochrane methodology we used the best estimate of effect size 207 
(rather than statistical significance) to assess whether effects occurred [17, 26].  RR <0.92 or >1.08 208 
was considered a relevant clinical effect (RR 0.92 to 1.08 was considered “little or no effect”), while 209 
mean difference between arms of ≥10% of baseline was required for a relevant clinical effect for 210 
continuous measures. Outcome data were interpreted using GRADE assessment, drafted by LH then 211 
discussed and agreed with WHO NUGAG [17].  Where GRADE suggested data of very low-quality 212 
we did not interpret effect sizes.  Where data were of low-quality we used the term “may”, moderate-213 
quality evidence warranted “probably” in describing effect sizes.  214 
 215 
Subgroup analysis  216 
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We subgrouped on the basis of intervention type, PUFA dose, trial duration, replacement, age, 217 
sex, baseline IBD severity, diagnosis of UC or CD, baseline levels of inflammatory markers and 218 
baseline medication use (corticosteroid, immunosuppressant or immuno-modulatory therapies). We 219 
were not able to subgroup by baseline PUFA intakes or change in omega-3/omega-6 ratio (as we had 220 
planned) as these data were rarely provided.   221 
  222 
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Results 223 
Description of studies 224 
Brief characteristics, risk of bias assessments and references of included IBD studies are 225 
outlined in Table 1, of trials providing data on IBD diagnosis in Table 2, and included trials providing 226 
data on inflammatory markers in Table 3, while characteristics of all included studies are detailed in 227 
Additional Table 1. Further additional tables, forest plots, funnel plots and details of all sensitivity 228 
analyses and subgroups are also found in the Additional Materials. 229 
We included 83 RCTs that measured at least one of our primary outcomes. These 83 RCTs (84 230 
comparison groups) randomised 41,751 participants. Eleven RCTs were assessed as at low summary 231 
risk of bias, Additional Figure 1 [35-45]. Forty four trials were conducted in Europe, 18 in North 232 
America; 4 in South America; 12 in Asia; 2 in Australia, and three across several continents. Thirteen 233 
studies specifically recruited participants with IBD (7 with UC [46-52], 6 with CD [37, 42, 53-55]), 234 
26 had CVD or raised lipids at baseline, 10 had diabetes, metabolic syndrome or raised insulin levels, 235 
11 had rheumatoid arthritis, 4 were overweight or obese, 5 were healthy adults, the remainder other 236 
conditions (2 lupus, 2 cognitive problems, 1 dry eyes, 1 mobility problems, 3 non-alcoholic 237 
steatohepatitis, 1 various, 1 other arthritis, 1 periodontitis, 1 raised breast density, 1 multiple sclerosis).  238 
Seventy trials assessed effects of LCn3, six effects of ALA, and three effects of omega-3 (it was 239 
unclear whether LCn3, ALA or both). Seven trials assessed effects of omega-6 compared to something 240 
other than omega-3, and two assessed effects of total PUFA (several trials compared more than two 241 
relevant arms). 242 
 243 
Effects of LCn3 in people with existing IBD 244 
Increasing LCn3 may reduce the risk of IBD relapse (low quality evidence, downgraded once 245 
each for imprecision and publication bias). GRADE assessment of certainty of evidence on effects of 246 
increasing LCn3 on IBD and inflammatory outcomes are detailed in Additional Table 2. Six trials 247 
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provided data on relapse in CD, four in UC.  Meta-analysis suggests reduction in relapse rates of IBD 248 
in those taking more LCn3 (RR 0.85, 95% CI 0.72 to 1.01, I2 30%, 521 relapses in 1196 participants, 249 
Figure 1), and this was maintained (and statistically significant) in fixed effects analysis, when 250 
retaining only trials at low summary risk of bias, trials at low risk from compliance problems and in 251 
larger trials (see Additional Table 3).  The funnel plot suggests that some small studies with increased 252 
rates of relapse in the intervention group may be missing (Additional Figure 2), but similarity in effect 253 
of fixed and random effects meta-analyses indicates this was not important. Data were mainly from 254 
CD trials, and subgrouping suggested there was no statistically significant difference in effect between 255 
CD and UC subgroups (Figure 1). There were no differences in effect when subgrouping by 256 
intervention type (though most studies were of supplementary capsules), dose, duration, age, sex, 257 
medications taken or baseline IBD status, but there was a greater effect in the subgroup where LCn3 258 
replaced saturated fats than other replacements (p=0.02, Additional Table 3).  259 
Increasing LCn3 may reduce the risk of IBD worsening (low quality evidence, downgraded 260 
once for risk of bias, once for imprecision). Two trials provided data on risk of worsening of CD, none 261 
on UC.  This limited data set suggested that LCn3 reduced risk of worsening CD (RR 0.85, 95% CI 262 
0.71 to 1.03, I2 0%, 271 participants disease worsened in 748 participants [54]).  This did not alter with 263 
fixed effects analysis, but neither study was at low summary risk of bias, or at low risk of compliance 264 
problems (Additional Table 4).  The effect of increasing LCn3 on IBD severity was unclear as the 265 
evidence was of very low quality (downgraded once for risk of bias, twice for imprecision). Data on 266 
disease severity were more limited than those for worsening, and included UC severity score, stool 267 
frequency, stool consistency and rectal bleeding (one trial each of 18 or 20 participants, only stool 268 
consistency included SDs to enable use in meta-analysis or assessment of statistical significance, 269 
Figure 2 [48, 56]).  Neither study was at low summary risk of bias.  270 
 271 
Effects of LCn3 on IBD diagnoses 272 
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Low quality evidence suggests that increasing LCn3 may increase the risk of developing IBD 273 
(downgraded twice for imprecision). We found limited data on diagnoses of colitis in two large trials 274 
(RR 1.10, 95% CI 0.63 to 1.92, I2 0%, 49 diagnoses in 16,015 participants, Figure 3 [36, 39]).  The 275 
suggestion of increased risk in those taking LCn3 did not alter with fixed effects analysis, limiting to 276 
trials at low summary risk of bias, low risk of compliance problems, or study size (Additional Table 277 
5). 278 
 279 
Effects of LCn3 on inflammatory biomarkers in people with and without IBD  280 
Higher levels of inflammatory biomarkers equate to more inflammation. The effect of 281 
increasing LCn3 on CRP was unclear as the evidence was of very low quality (downgraded once each 282 
for inconsistency, imprecision and publication bias). Thirty-nine trials assessed effects of LCn3 on 283 
CRP over at least 6 months, thirteen reporting CRP, twenty-six high sensitivity CRP (hs-CRP), but 284 
only 26 provided enough data to be included in meta-analysis. No included studies specifically 285 
recruited people with IBD at baseline. As there were not statistically significant differences between 286 
CRP and hs-CRP subgroups, we pooled the results of both in all analyses. Baseline CRP ranged from 287 
<1 to under 10mg/L with a single trial having a baseline of 18 mg/L [57].  As the data were very 288 
different in different trials we assumed this reflected differing analysis methods so ran the analyses 289 
using standardised mean difference (SMD).  This suggested little or no effect of increasing LCn3 on 290 
CRP (SMD -0.09, 95% CI -0.21 to 0.03, I2 68%, in 15,278 participants, Figure 4). Translating this 291 
back into mg/L using the AlphaOmega trial (the trial taking most weight in the meta-analysis [58]) 292 
suggested a less than 10% fall in CRP with LCn3.  This lack of effect did not alter in sensitivity 293 
analyses by summary risk of bias, compliance or study size, but fixed effects analysis suggested a 294 
clinically insignificant but statistically significant effect (SMD -0.06, 95% CI -0.12 to -0.01, I2 68%, 295 
in 15,278 participants, Additional Table 6).  The funnel plot suggested that some studies with lower 296 
CRP in the LCn3 arm may be missing, if these studies were added back they would suggest a greater 297 
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reduction by LCn3 of CRP (Additional Figure 3). There were no important differences between 298 
subgroups by intervention type, dose, duration, replacement, age, sex, medication used or baseline 299 
disease status (Figure 5 & Additional Table 6). 300 
Moderate quality evidence suggests that increasing LCn3 probably reduces ESR (downgraded 301 
once for imprecision). Seven trials assessed effects on ESR in the long-term, of which 6 were combined 302 
using SMD, suggesting a statistically significant reduction in those taking more LCn3 (SMD -0.23, 303 
95% CI -0.44 to -0.01, I2 0%, in 368 participants, Additional Table 7).  The effect remained statistically 304 
significant in fixed effects analysis and limiting to trials at low summary risk of bias (MD -305 
14.00mm/hour, 95% CI -25.33 to -2.67, 1 trial [37]) but the statistical significance was lost when 306 
limiting by compliance.  The single trial at low summary risk of bias was the single trial that included 307 
people with IBD, reporting the effect of 2.7g/d LCn3 taken as a supplementary capsule over 12 months 308 
on ESR in 78 participants with CD at baseline. It suggested statistically significant reduction in ESR 309 
with higher LCn3 intake (MD -14.0mm/hour, 95% CI -25.3 to -2.7)[37].  No funnel plot, further 310 
sensitivity analyses or subgrouping was carried out as there were so few trials. As there was no 311 
difference in effect size whether random or fixed-effects analyses were carried out there was unlikely 312 
to be important small study bias. 313 
The effect of increasing LCn3 on IL-6 was unclear as the evidence was of very low quality 314 
(downgraded once each for risk of bias, inconsistency and imprecision). Twenty-two trials assessed 315 
effects on IL-6 over at least 6 months, of which 18 were combined using SMD in random effects meta-316 
analysis (SMD -0.35, 95% CI -0.62 to -0.07, I2 83%, in 2234 participants, Figure 6).  The suggestion 317 
of reduction in IL-6 was highly heterogeneous, and the funnel plot was not interpretable (Additional 318 
Figure 4), but effects using fixed and random-effects analyses were very similar so small study bias is 319 
unlikely.  The statistically significant reduction in IL-6 in those with higher LCn3 intake was also seen 320 
in the sensitivity analyses using fixed effects and studies at low risk from compliance problems, but 321 
statistical significance was lost when analyses were limited to trials at low summary risk of bias and 322 
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larger trials (Additional Table 8). There was no clinically or statistically significant effect in the single  323 
trial in people with existing IBD (32 participants with UC, MD 0.07pg/ml, 95% CI -0.15 to 0.29)[46]. 324 
There were no differences between subgroups for intervention type, LCn3 dose, duration, replacement, 325 
age or baseline health conditions, but there was a suggestion of greater effects in men.  There were 326 
also suggestions of different effects in different age groups, but there were no clear progressions so 327 
this was probably spurious.  328 
Increasing LCn3 may increase faecal calprotectin (low quality evidence, downgraded twice for 329 
imprecision). One trial reported faecal calprotectin, in only 34 participants with UC at baseline, 330 
suggesting a non-statistically significant increase with higher LCn3 (MD 16.1 μg/g, 95% CI -37.6 to 331 
69.8, 34 participants[46]). This single trial was at low summary risk of bias and low risk from 332 
compliance problems. 333 
Effects of LCn3 on TNF-α, ICAM-1 and VCAM-1 were collated as secondary outcomes (Table 334 
3, Additional Table 9), and GRADE was not assessed. None of the trials in people with existing IBD 335 
reported any of these markers. Eighteen trials reported effects of LCn3 on TNF-α in pg/ml, of which 336 
14 could be included in meta-analysis.  The forest plot suggested that LCn3 reduced TNF-α (SMD -337 
0.45, 95% CI -0.81 to -0.09, I2 86%, 1774 participants, Additional Figure 5), but none of these trials 338 
were at low summary risk of bias and the funnel plot was not interpretable (Additional Figure 6). Five 339 
trials reported ICAM-1 in ng/ml of which three could be included in meta-analysis, suggesting no 340 
effect of LCn3 on ICAM-1 in the longer term (SMD 0.04, 95% CI -0.43 to 0.50, I2 74%, 639 341 
participants, not shown).  Meta-analysis of the three of four trials reporting effects of LCn3 on VCAM-342 
1 suggested no effect (SMD -0.18, 95% CI -0.87 to 0.51, I2 88%, 388 participants, Additional Table 343 
9).  344 
 345 
Effects of LCn3 on other secondary outcomes, medication use and quality of life 346 
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Medication use was rarely reported, but one trial provided data on percentage of baseline non-347 
steroidal anti-inflammatory drug (NSAID) use, suggesting that NSAID use was lower with higher 348 
LCn3 (MD -43.5%, 95% CI -71.4 to -15.6, 64 participants [59]). This single trial was not at low 349 
summary risk of bias. Similarly, a single trial reported quality of life, assessed using the Health Activity 350 
questionnaire (HAQ), suggesting similar levels of quality of life with higher and lower LCn3 intake 351 
(MD -0.02, 95% CI -0.12 to 0.08, 130 participants, the trial was not at low summary risk of bias [60]). 352 
Details of effects of LCn3 on measures of adiposity are systematically reviewed (as primary outcomes) 353 
in a sister review, so not discussed here [18]. 354 
 355 
Effects of ALA  356 
The GRADE table on effects of increasing ALA on primary outcomes is Additional Table 10. 357 
We found no data on effects of increasing ALA on people with IBD on remission or relapse, severity, 358 
worsening, or medication use, on inflammatory markers, or in diagnosis of IBD in people without IBD 359 
at baseline. Four trials (in people without existing IBD but with CVD risk factors) assessed effects of 360 
increasing ALA intake (up to 2 g/day) for 12 to 40 months on CRP.  Baseline CRP was 1.8 to 4.9 mg/L 361 
(mean 3.8 mg/L).  Meta-analysis and GRADE suggested high quality evidence of little or no effect 362 
(SMD -0.00, 95% CI -0.08 to 0.07, I2 0%, 2715 participants, Additional Figure 7, MD -0.00mg/L, 95% 363 
CI -0.16 to 0.16, I2 0%).  This did not alter in fixed effects analysis, limiting to the three trials at low 364 
summary risk of bias, or at low risk of compliance problems (Additional Table 11).  Two of the three 365 
trials assessing effects of ALA on IL-6 were included in meta-analysis, suggesting low quality 366 
evidence of little or no effect (SMD -0.04, 95% CI -0.33 to 0.24, I2 0%, 186 participants, neither trial 367 
at low summary risk of bias, Additional Figure 8, MD -0.28pg/ml, 95% CI -1.09 to 0.53, I2 0%, quality 368 
of evidence downgraded for once for imprecision, once for risk of bias).  Effects did not differ by fixed 369 
or random-effects analysis, Additional Table 12. Two trials reported on TNF-α, suggesting little effect 370 
of increasing ALA (SMD -0.18, 95% CI -0.51 to 0.14, I2 0%, 146 participants, Additional Figure 9), 371 
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which did not differ in the single trial at low summary risk of bias.  No trials reported on effects of 372 
ALA on ESR, faecal calprotectin, ICAM-1 or VCAM-1 or other secondary outcomes.  373 
 374 
Effects of omega-6  375 
The GRADE table for omega-6 is Additional Table 13. We found no data on effects of 376 
increasing omega-6 on people with IBD on worsening or medication use, or inflammatory markers, or 377 
in diagnosis of IBD in people without IBD at baseline.  The effects of increasing omega-6 on IBD 378 
relapse and severity were unclear as the evidence for both were of very low quality. Limited 379 
information was provided on relapse (2 of 20 people with UC relapsed, RR 0.54, 95% CI 0.04 to 7.36) 380 
and severity by a single trial of 20 people, providing data suggesting slightly greater but non-381 
statistically significant stool solidity (MD -0.30, 95% CI -0.73 to 0.13, on a scale of 0 to 2, with 0 382 
being solid and 2 watery, 20 participants [48]). Data from the same study on stool frequency and rectal 383 
bleeding did not include measures of variance, so statistical significance was not clear. 384 
Low quality evidence suggests that increasing omega-6 may have little or no effect on CRP 385 
(downgraded once each for risk of bias and imprecision).  Meta-analysis of two of three trials assessing 386 
effects of omega-6 on CRP suggested little or no effect (SMD 0.09, 95% CI -0.17 to 0.35, I2 0%, 228 387 
participants, MD 0.19mg/L, 95% CI -0.28 to 0.66, neither trial was at low summary risk of bias, the 388 
third trial provided no data on variance. Effects did not differ when using fixed instead of random-389 
effects meta-analysis, Additional Table 14.  The effect of increasing omega-6 on ESR is unclear as the 390 
evidence is of very low quality (downgraded once for risk of bias, twice for imprecision). One of three 391 
trials assessing effects of omega-6 on ESR provided a measure of variance suggesting no effect (MD 392 
4.00mm/hour, 95% CI -10.55 to 18.55, 75 participants without baseline IBD, not at low summary risk 393 
of bias, Additional Table 15).  We found no studies assessing effects of omega-6 on IL-6, faecal 394 
calprotectin, ICAM-1, VCAM-1 or other secondary outcomes.  A single trial assessed effects of 395 
omega-6 on TNF-α (MD -0.40, 95% CI -0.95 to 0.15, 38 participants, not at low summary risk of bias).  396 
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 397 
Effects of total PUFA  398 
We found no studies assessing effects of total PUFA on IBD relapse, worsening, severity, 399 
medication use or inflammatory markers in people with IBD or on IBD diagnosis in people without 400 
IBD at baseline, see GRADE table, Additional Table 16. Long-term effects of increasing total PUFA 401 
on CRP are unclear as the evidence is of very low quality. Three of five trials assessing effects of 402 
increasing total PUFA intake (up to 27.6 g/day for a duration of 6 to 56 months) on CRP could be 403 
included in meta-analysis, suggesting no effect of total PUFA on CRP (SMD 0.25, 95% CI -0.10 to 404 
0.60, I2 50%, 385 participants, Figure 7, Additional Table 17). The single trial assessing ESR did not 405 
provide any measure of variance.  Increasing total PUFA may have little or no effect on IL-6, low 406 
quality evidence (downgraded once each for risk of bias and imprecision). Two trials reporting effects 407 
of total PUFA on IL-6 suggested no effect (SMD -0.09, 95% CI -0.24 to 0.07, I2 0%, 611 participants 408 
without IBD, neither trial was at low summary risk of bias, MD -0.08 pg/ml, 95% CI -0.18 to 0.02, 409 
Figure 6, Additional Table 18). No trials assessed effects of total PUFA on faecal calprotectin or 410 
secondary outcomes.   411 
 412 
  413 
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Discussion  414 
This is the most comprehensive meta-analysis of RCTs investigating long-term effects of 415 
omega-3, omega-6 and total PUFA on treatment and prevention of IBD and on inflammatory markers 416 
in people with and without IBD at baseline. We systematically reviewed the effects of omega-3, 417 
omega-6 and total PUFA on IBD outcomes, including 83 RCTs (41,751 participants), of which 13 418 
recruited people with IBD and 11 were at low summary risk of bias.  Low quality evidence suggested 419 
increasing LCn3 may reduce the risk of IBD relapse and worsening, and reduce ESR, but increase the 420 
risk of IBD diagnosis and increase faecal calprotectin. Only one included trial (of LCn3) assessed 421 
effects on faecal calprotectin, limiting our ability to draw conclusions on the effect of omega-3, omega-422 
6 and PUFAs on this important biomarker. Evidence on effects of increasing ALA, omega-6 and total 423 
PUFA were sparse, but increasing ALA has little or no effect on CRP and may have little effect on IL-424 
6.  Increasing omega-6 may have little or no effect on CRP and increasing total PUFA may have little 425 
or no effect on IL-6.  Evidence for other primary outcomes was of very low quality or absent. Data on 426 
inflammatory markers was often not useable in meta-analysis due to missing variance data or not being 427 
reported numerically despite being measured, so there is considerable inherent risk of small study bias. 428 
Evidence for effects of PUFA on inflammatory markers in people with existing IBD is very limited. 429 
We were interested in how effects varied by UC and CD, intervention type, baseline severity, 430 
dose, duration and nutrients displaced by increased PUFA.  For trials with participants with existing 431 
IBD, the duration of intervention ranged from 6 to 24 months, and LCn3 doses were from 1.12 to 4.5 432 
g EPA/day plus 0.73 to 2.4 g DHA/day. Where there were enough data to subgroup effects rarely 433 
varied according to these variables, which may be due to limited data or to lack of effect of these 434 
variables. 435 
Our findings on effects of increasing LCn3 appear contradictory, suggesting reduction in IBD 436 
relapse, reduced risk of IBD worsening but increased the risk of developing IBD.  A recent systematic 437 
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review of observational studies reflects this dissonance suggesting significant negative correlations 438 
between fish consumption and CD incidence, and between LCn3 intake and UC risk, but no 439 
associations between total dietary omega-3 or ALA intake and IBD incidence [61]. The Nurses’ Health 440 
Study suggested that energy-adjusted intake of omega-6 or omega-3 was not associated with risk of 441 
UC or CD but there was a (non-statistically significant) suggestion of a negative association between 442 
LCn3 intake and UC risk [62].  On the other hand, a systematic review of trials found that LCn3 443 
supplements were probably ineffective for maintaining remission in CD [63]. Despite strong 444 
theoretical mechanisms for utility of LCn3 and negative effects of omega-6 on IBD and the 445 
inflammatory process [8], current evidence is contradictory. The trials included in this systematic 446 
review assessed effects of increasing LCn3 primarily through consumption of fish oil supplements.  A 447 
diet high in oily fish would increase LCn3 intake, but also iodine, protein, selenium etc so may have 448 
different effects. Overall, this lack of clarity is reflected in the lack of guidelines on LCn3 449 
supplementation in IBD management [5, 64-68], though the European Society of Parenteral and 450 
Enteral Nutrition (ESPEN) specifically advises that a diet high in LCn3 and low in omega-6 is 451 
preventative of IBD (based on individual observational studies), but against LCn3 supplementation for 452 
maintenance of remission [69].  453 
As we were interested in the mechanism of any effects of PUFAs via inflammatory processes 454 
on IBD, we took the novel step of also assessing effects of omega-3, omega-6 or PUFAs on 455 
inflammatory biomarkers. Clear effects on inflammatory biomarkers could support assertions of anti- 456 
or pro-inflammatory mechanisms of action and support effects on IBD outcomes. To underpin effects 457 
on IBD we would expect to find that increasing LCn3 and ALA would reduce CRP, ESR, IL-6 and 458 
faecal calprotectin, while increasing omega-6 and total PUFA (including all omega-3 and omega-6 459 
fatty acids) would increase these markers. These effects were not seen in our included long-term trials, 460 
except that increasing LCn3 appears to reduce ESR (in people with and without IBD) but increases 461 
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faecal calprotectin, a specific marker for IBD, in people with IBD.  This provides little or no evidence 462 
to support pro- or anti-inflammatory effects of increasing LCn3, ALA, omega-6 or total PUFA intakes.   463 
Despite measurement in 39 trials the evidence of long-term effects of LCn3 on CRP was of 464 
very low quality, so effects were unclear, highlighting a need for standardisation of measurement (CRP 465 
vs hs-CRP) and reporting. As CRP and ESR are identified as having a role in monitoring disease 466 
activity and response to treatment [5, 64, 67], and correlate with IBD diagnosis [70], their lack of 467 
response to omega-3 or omega-6 fats in this review undermines the effect of omega-3 and omega-6 468 
fats both on inflammation and on IBD.  As faecal calprotectin is a specific and sensitive inflammatory 469 
biomarker for IBD diagnosis, progression and severity [5, 64, 65, 70, 71] effects of omega-3 and 470 
omega-6 on faecal calprotectin are particularly important.  However, only one included trial (of LCn3) 471 
assessed effects on faecal calprotectin, limiting our ability to draw conclusions on the effect of omega-472 
3, omega-6 and PUFAs on this important biomarker.  473 
Most included studies measured IBD diagnosis, severity or progression or inflammatory 474 
biomarkers. Measuring medication use and quality of life in people with IBD are equally as important 475 
in measuring the impact of IBD on patients, and identifying and measuring outcomes that are important 476 
to patients is the gold standard of high quality clinical research [72]. However, these outcomes were 477 
rarely measured or reported, suggesting that this message has not been adequately received by those 478 
conducting IBD research, and supporting the need for a core outcome set in IBD research that captures 479 
clinically relevant and patient-centred metrics [73].  480 
  481 
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Conclusion 482 
Despite rigorous searching for relevant trials, data are sparse on long-term effects of ALA, 483 
omega-6 and total PUFA on clinical outcomes in IBD, prevention of IBD, and on inflammatory 484 
markers in people with and without IBD. Methodologically only 11 of 83 included trials were at low 485 
summary risk of bias, none of the seven trials in people with existing UC, and two of the six trials of 486 
people with existing CD. Future trials of effects of fatty acids on IBD, and on inflammatory markers, 487 
need to be of high methodological quality, using strong randomisation, allocation concealment, 488 
masking of participants and outcome assessors, so that results are less susceptible to inherent bias. As 489 
effects of LCn3 on IBD outcomes are contradictory, interpretation of results is difficult. Currently, 490 
combined findings from clinical and biomarker outcomes suggest little or no effect of LCn3 on IBD 491 
or inflammation.  492 
There is a pressing need for high quality, well designed research using a core outcome set to 493 
assess effects of interventions, particularly effects of increasing omega-3 and omega-6 fats, on IBD 494 
diagnosis, progression, inflammatory biomarkers (particularly faecal calprotectin), medication use, 495 
and quality of life.  Additionally, existing trials of omega-3 and omega-6 interventions would ideally 496 
report IBD diagnoses to allow assessment of preventive effects.  497 
 498 
  499 
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Table 1. Brief characteristics of the 13 trials that assessed effects of PUFA on people with existing 500 
IBD (for full details see Additional Table 1).  501 
 502 
Study name & 
references 
Participants Intervention & comparison, 
duration, dose 
Summary 
risk of bias 
Almallah 1998 
[47, 56] 
Individuals with ulcerative 
colitis with only distal disease 
(Europe) 
n3 EPA+DHA vs n6 LA, 6 




Belluzzi 1996   
[37] 
Individuals with established 
diagnosis of CD in clinical 
remission (Europe) 
n3 EPA+DHA vs mixed fat, 12 





Individuals with CD in 
remission 1 month after ileal 
resection (Europe)  
n3 EPA+DHA vs mixed fat), 12 






Adults with quiescent CD and 
CDAI score <150 (Europe, 
North America & Asia) 
n3 EPA vs mixed fats, 52 weeks, 





Adults with a confirmed CD 
and CDAI score <150 and 
responding to steroid induction 
therapy (Europe, North 
America & Asia) 
n3 EPA+DHA vs mixed fats, 58 





Pot 2009 [46, 
74, 75]  
Adults with colorectal polyps, 
inactive UC or no macroscopic 
signs of disease, given 
colonoscopy (Europe) 
high n3 fish diet vs low n3 fish 
diet vs low fish diet, 6 months, 






People with stable UC for >1 
year and on <10mg 
prednisolone/day (Europe) 
n3 EPA vs n6 GLA vs MUFA, 6 






People with established UC 
with ≥2 relapses in past 3 years 
(Europe) 
n3 EPA vs MUFA, 12 months, 





People with UC in remission 
(Europe) 
n3 EPA+DHA vs n6 LA, 24 





People with CD in remission 
(but with a recent relapse) 
(Europe) 
n3 EPA+DHA vs n6 LA, 12 





People with UC in clinical, 
endoscopic & histological 
remission (Europe) 
n3 EPA+DHA Vs MUFA, 12 




Mate 1991  [55] People with CD in remission 
(Europe) 






People with active extensive 
UC (Europe) 
n3 vs n6, 6 months, 5.6mg/d (sic) 






ALA = alpha-linolenic acid  505 
CD = Crohn’s disease 506 
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CDAI = Crohn’s disease activity index 507 
DHA = docosahexaenoic acid  508 
EPA = eicosapentaenoic acid or icosapentaenoic acid  509 
GLA = gamma linolenic acid 510 
LA = linoleic acid 511 
LCn3 = long-chain omega 3 512 
MUFA = mono-unsaturated fatty acids  513 
n3 = omega 3 514 
n6 = omega 6 515 
UC = Ulcerative colitis 516 
 517 
  518 
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Table 2. Characteristics of included studies with data on prevention of IBD, including risk of bias 519 
and references  520 
 521 
Study name & 
references 
Participants Intervention & comparison, duration, 
dose 
Summary 
risk of bias 
ASCEND 2012 
[36, 76] 
People with DM, without 
apparent vascular disease  
n-3 EPA + DHA vs MUFA, median 7.4 
years, 460mg/d EPA + 380mg/d DHA 
Low 
DREAM Asbell 
2018 [39, 77] 
Adults with dry eye 
 





DHA = docosahexaenoic acid 524 
DM = diabetes mellitus 525 
EPA = eicosapentaenoic acid or icosapentaenoic acid 526 
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Table 3. Characteristics of included studies reporting markers of inflammation, including risk of bias 532 
and references  533 
 534 
Study name & 
references 
Participants Intervention & comparison, duration, 
dose 
Summary 
risk of bias 
AFFORD 
2014  [78, 79] 
People with symptomatic 
paroxysmal or persistent AF 
n3 EPA+DHA vs n6, 12 months, 1.6g/d 




ALA [35, 80] 
60-80 year olds with previous 
MI 






60-80 year olds with previous 
MI 











Drug-naive patients with type 2 
DM 




Belch 1988 [83] People with classical or 
definite RA 
n6 GLA vs n6 GLA + n3 EPA vs nil, 12 
months, EPA 0.24g/d + GLA 0.45g/d 
Moderate 
to high 
Belluzzi 1996   
[37] 
Individuals with established 
diagnosis of CD in clinical 
remission 
n3 EPA+DHA vs mixed fat, 12 months, 




People with RA n3 EPA+DHA vs n6 LA, 24 weeks, 
1.8g/d EPA & 1.2g/d DHA 
Moderate 
or high 
Bo 2017 [84] Older adults with mild 
cognitive impairment 
n3 EPA+DHA vs MUFA), 6 months, 480 
mg/d DHA and 720 mg/d EPA 
Moderate 
or high 
Brox 2001 [85] Subjects with moderate 
hypercholesterolaemia 
 
n3 EPA+DHA from cod liver vs n3 
EPA+DHA from seal oil vs nil, 14 
months, seal oil 1.1g/d EPA + 1.5/d 






People with rheumatoid 
arthritis and upper GI lesions 
due to NSAID intake 




Clark 2016 [38] Adults with impaired glucose 
metabolism or type 2 diabetes 
mellitus 





People with paroxysmal or 
persistent AF 
n3 EPA+DHA vs n6 LA, 6 months, 
1.86g/d EPA & 1.5g/d DHA 
Moderate 
or high 
de Luis 2016 
[88] 
Generally healthy individuals 
with obesity 
n3 DHA vs MUFA, 6 months, 500mg/d 





Adults with combined 
dyslipidaemia 
n3 EPA+DHA vs non-fat placebo, 6 





Adults with combined 
lipidaemia 
n3 EPA+DHA vs non-fat placebo, 6 







n3 EPA+DHA (3 different doses) vs 
MUFA, 12 months, 1.12g/d; 2.24g/d or 
3.37g/d EPA + DHA 
Moderate 
or high 
DO IT - Einvik 
2010 [94-99] 
Elderly men with long standing 
dyslipidaemia or hypertension 
n3 DHA+EPA vs n6 LA, 36 months, 






People with metabolic 
syndrome 
n3 EPA+DHA vs nil, 6 months, 180mg/d 
EPA, 120mg/d DHA 
Moderate 
or high 
ELIA - Takaki 
2011 [101] 
People with CAD and 
dyslipidaemia on statins 
n3 EPA vs nil, 11 months, 1.8g/d EPA Moderate 
or high 
ENRGISE 2016 
[102-104]   
People aged 70+ years with 
walking or stair-climbing 
difficulty 
LCn-3 vs PUFA, 12 months, 0.8g/d EPA 





People with non-alcoholic 
steatohepatitis (NASH) and 
non-alcoholic fatty liver 
disease (NAFLD) 
n3 EPA, low dose vs high dose vs 






Adults with quiescent CD and 
CDAI score <150 
n3 EPA vs mixed fats, 52 weeks, 2.2g/d 





Adults with a confirmed CD 
and CDAI score <150 and 
responding to steroid induction 
therapy 
n3 EPA+DHA vs mixed fats, 58 weeks, 






Healthy older adults with no 
cognitive impairment 
n3 EPA+DHA vs MUFA, 18 months, 




People with chronic heart 
failure 






People with hyperlipidaemia n3 EPA+DHA vs n3 ALA vs n6 LA, 6 
months, 1.7g/d or 0.8g/d EPA+DHA, 




Pot 2009 [46, 
74, 75]  
Adults visiting the hospital for 
colonoscopy with colorectal 
polyps, inactive UC or no 
macroscopic signs of disease 
high n3 fish diet vs low n3 fish diet vs 








People with peripheral artery 
disease 





People with persistent atrial 
fibrillation 








n3 EPA+DHA vs n6 LA, 6 months, 1.3g 





People with definite or classic 
active RA 
n3 EPA+DHA vs n6 LA), 6 or 7 months, 















Lalia 2015 [119] Insulin resistant adults 
 
n3 EPA+DHA vs MUFA, 6 months, 
2.7g/d EPA+ 1.2g/d DHA 
Moderate 
or high 
Lau 1993 [59] People with definite or 
classical RA requiring NSAIDs 
n3 EPA+DHA vs nil), 12 months, 1.71g 





People with RA and active 
synovitis 
n6 GLA vs mixed fats including LA, 24 





People with RA and active 
synovitis 





Li 2015 [122] People diagnosed with 
pathological non-alcoholic 
steatohepatitis (NASH) 






2002 [43, 123] 
Hypercholesterolaemic adults 
with 2 or more CVD risk 
factors 




Non-smoking men and women 
aged 45-70y 
n-3 EPA+DHA at three different doses 
vs MUFA, 12 months, 0.45g/d or 0.9g/d 




People treated for chronic 
periodontitis 
n3 EPA+DHA vs unclear, 12 months, 
0.18g/d EPA, 0.12g/d DHA 
Moderate 
or high 
Mate 1991  [55] People with Crohn’s Disease in 
remission 




MENU - Rock 
2016 [125] 
Overweight and obese women, 
of whom half were insulin 
resistant 




Overweight or obese adults 
 
high LCn3 & high ALA vs high LCn3 & 
n6 vs low LCn3 & high ALA vs low 
LCn3 & n6, also a control arm), 6 






Middle-aged men and women 
with metabolic syndrome 




Niki 2016 [128] Patients with angina and 
hypertension treated with 
strong statins 






People with untreated 
dyslipidaemia and thin-cap 
fibroatheroma 
n3 EPA vs nil, both with statin, 9 





People with cardiomyopathy 
and frequent or repetitive 
ventricular arrhythmia 
n3 EPA+DHA vs MUFA, 6 months, 
0.87g/d EPA + 1.44g/d DHA 
Moderate 
or high 
Nodari 2011 HF 
[131] 
People with heart failure (non-
ischaemic dilated 
cardiomyopathy) 
n3 DHA+EPA vs MUFA, 12 months, 





Patients with non-alcoholic 
steatohepatitis 
n3 EPA+DHA vs non-fat, 6 months, 




OFAMI - Nilsen 
2001 [133]  
Patients recruited 4-8 days 
after confirmed MI 







People after acute MI 
 
n3 EPA+DHA vs n6 LA, 6 months, 





People with mild to moderate 
Alzheimer's disease & stable 
comorbidities 
n3 EPA+DHA vs. n6 LA, 6 months, 
1.72g/d DHA + 600 mg EPA 
Moderate 
or high 
ORL 2013 [144] Adults with 
hypertriglyceridaemia 
n3 EPA+DHA high dose vs low dose vs 




g/d DHA or 0.93g/d EPA + 0.75g/d 
DHA 
Patch 2005 
[145, 146]  
Healthy overweight people 
with mild TG elevation 






Men (55-80 years) & women 
(60-80 years), free of CVD but 
with diabetes or ≥3 CVD risk 
factors 







People with relapsing remitting 
multiple sclerosis 
n3 EPA+DHA vs n6 LA, 12 months, 




2018 [153, 154] 
People with 
hypertriglyceridaemia, and 
with CVD or with DM and 
another risk factor, and on 
statin  




Reed 2014 [45] Adults with RA n3 EPA+DHA vs n6 GLA, 18 months, 





women with high breast 
density  
n-3 vs nil, 24 months, 1.86 g/d EPA + 





People with newly-diagnosed 
impaired glucose metabolism 
and CAD 




People with stable RA n3 EPA+DHA vs n6, 6 months, 1.8g/d 






Women with early stage breast 
cancer receiving an aromatase 
inhibitor with musculoskeletal 
pain 
n3 EPA+DHA vs n6 LA, 6 months, 





Healthy adult volunteers with 
BMI 25-35 kg/m2 




Tani 2017 [160] People with stable CAD on 
statins 






Postmenopausal women with 
metabolic syndrome 
n3 EPA+DHA vs nil, 6 months, 0.54g/d 







n3 EPA+DHA vs nil, 6 months, 540 





Recent survivors of first 
myocardial infarction 






Overweight/obese type 2 DM 
patients treated with metformin 
n3 EPA+DHA vs n6 LA, 6 months, 




2014 [166, 167] 
People with stable coronary 
artery disease 




Adults with a long-term 
systemic lupus erythematosus 






Healthy older adults (50-80 
years) 
n3 EPA+DHA vs n6 LA, 6 months, 






People with systemic lupus 
erythematosus  
n3 EPA+DHA vs MUFA, 6 months, 





AF = atrial fibrillation 537 
ALA = alpha-linolenic acid 538 
BMI = body mass index 539 
CABG = coronary artery bypass grafting 540 
CAD = coronary artery disease 541 
CHD = coronary heart disease 542 
CVD = cardiovascular disease 543 
DBP = diastolic blood pressure 544 
DHA = docosahexaenoic acid 545 
DM = diabetes mellitus 546 
DPA = docosapentaenoic acid 547 
E = dietary energy 548 
EPA = eicosapentaenoic acid or icosapentaenoic acid 549 
HDL = high density lipoprotein 550 
HRT = hormone replacement therapy 551 
HT = hypertension 552 
LA = linoleic acid 553 
LCn3 = long-chain omega 3 554 
MI = myocardial infarction 555 
MUFA = mono-unsaturated fatty acids 556 
n3 = omega 3 557 
n6 = omega 6 558 
PUFA = poly-unsaturated fatty acids 559 
PTCA = percutaneous 560 
RA = rheumatoid arthritis 561 
SFA = saturated fatty acids 562 
TG = serum triglycerides 563 
TIA = transient ischaemic attack 564 
 565 
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